Forschungsdatenbank PMU-SQQUID

Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial.
Kasner, SE; Swaminathan, B; Lavados, P; Sharma, M; Muir, K; Veltkamp, R; Ameriso, SF; Endres, M; Lutsep, H; Messé, SR; Spence, JD; Nedeltechev, K; Perera, K; Santo, G; Olavarria, V; Lindgren, A; Bangdiwala, S; Shoamanesh, A; Berkowitz, SD; Mundl, H; Connolly, SJ; Hart, RG;
Lancet Neurol. 2018; 17(12): 1053-1060.
Originalarbeiten (Zeitschrift)

Abstract/Keywords Web of Science PubMed Full Text

PMU-Autor/inn/en

Mutzenbach Sebastian

Abstract

Patent foramen ovale (PFO) is a contributor to embolic stroke of undetermined source (ESUS). Subgroup analyses from previous studies suggest that anticoagulation could reduce recurrent stroke compared with antiplatelet therapy. We hypothesised that anticoagulant treatment with rivaroxaban, an oral factor Xa inhibitor, would reduce the risk of recurrent ischaemic stroke compared with aspirin among patients with PFO enrolled in the NAVIGATE ESUS trial.